Glaukos Corp

Organisation

One Glaukos Way, Aliso Viejo, CA, United States, 92656

Headquarters

1094

Employees

Health Technology

Industry

Thomas Burns

Glaukos Corporation, an ophthalmic pharmaceutical and medical technology company, develops therapies for the treatment of glaucoma, corneal disorders, and retinal diseases in the United States and internationally. It offers iStent and iStent inject W micro-bypass stents designed to treat mild-to-moderate open-angle glaucoma through the restoration of the natural physiologic outflow pathways for aqueous humor. The company also provides iStent infinite indicated for use in the treatment of patients with glaucoma uncontrolled by prior medical and surgical therapy; and iDose TR, an intracameral procedural pharmaceutical therapy indicated for the reduction of intraocular pressure in patients with open-angle glaucoma or ocular hypertension. In addition, the company develops iLink, a device used for the treatment of keratoconus without the removal of the epithelium; ILution, a platform of cream-based drug formulation applied to the outer surface of the eyelid for drop less transdermal delivery of pharmaceutically active compounds for the treatment of anterior segment eye disorders; and retinal XR platform to treat age-related macular degeneration, diabetic macular edema, retinal vein occlusion, and other posterior segment retinal diseases. It sells its products to ambulatory surgery centers, hospitals, and physician private practices through a direct sales organization, direct sales subsidiaries, and distributors. The company was formerly known as Transdx, Inc. Glaukos Corporation was incorporated in 1998 and is headquartered in Aliso Viejo, California.

Price

Target

Glaukos Corp (GKOS) Price vs Consensus Price Target

As per the chart shown above, analysts believe that the Glaukos Corp (GKOS) share price will touch around $138.75 in next 12-months.

Currently 20 wall-street analysts regularly analyze the financials of Glaukos Corp on a frequent basis to provide recommendations along with target share price. 20 analysts offering 12-month price forecasts for Glaukos Corp (GKOS) have a share price target of $138.75. This median of share price forecast represents a 19.02% upside from the latest price of $116.58 as on 07.04.26.

Glaukos Corp (GKOS) Share Price Forecast

Home

US Stocks

Glaukos Corp (GKOS)

Glaukos Corp Stock Forecast

Glaukos Corp Stock Forecast & Price Target (Analyst Recommendation) | INDmoney

Percentage Difference

Glaukos Corp (GKOS): Difference between Current Price & Median Forecasted Price

Below is a chart showing the percentage difference between Glaukos Corp's share price and its median forecast price. As on 07.04.26, the difference is -18.82%

Glaukos Corp Forecast and Target Price

Glaukos Corp (GKOS) Share Price Forecast

Glaukos Corp (GKOS) Price vs Consensus Price Target

Glaukos Corp (GKOS) Share Price Forecast v/s Share Price Today

Glaukos Corp (GKOS): Difference between Current Price & Median Forecasted Price

Glaukos Corp (GKOS) Share Price Technical Analysis

50 Day Moving Average v/s Current Share Price

200 Day Moving Average v/s Current Share Price